Related references
Note: Only part of the references are listed.THE EFFECTS OF COMORBIDITY AND AGE ON RTOG STUDY ENROLLMENT IN STAGE III NON-SMALL CELL LUNG CANCER PATIENTS WHO ARE ELIGIBLE FOR RTOG STUDIES
Selim Firat et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Impact of Charlson's comorbidity index on overall survival following tumor nephrectomy for renal cell carcinoma
M. Hammad Ather et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Prognostic Factors in Elderly Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy
Jian Li et al.
ONCOLOGY (2009)
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE):: A randomized, phase II study
Lucio Crino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
Paul Wheatley-Price et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group trial 4599
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database
Taofeek K. Owonikoko et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC)
C. P. Belani et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II clinical trial of chemotherapy-naive patients >= 70 years of age treated with erlotinib for advanced non-small-cell lung cancer
David M. Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group trial (WJTOG 9904)
Shinzoh Kudoh et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients:: description and comparison with the Charlson's index
B Colinet et al.
BRITISH JOURNAL OF CANCER (2005)
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy:: A prognostic analysis of the Multicenter Italian Lung Cancer in the Elderly Study
P Maione et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Lung resection for non-small-cell lung cancer in patients older than 70:: Mortality, morbidity, and late survival compared with the general population
Ö Birim et al.
ANNALS OF THORACIC SURGERY (2003)
Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy
M Froehner et al.
UROLOGY (2003)
Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension
MT Gettman et al.
JOURNAL OF UROLOGY (2003)
Chemotherapy for elderly patients with advanced non-small-cell lung cancer:: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
C Gridelli et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
The impact of co-morbid disease on cancer control and survival following radical cystectomy
DC Miller et al.
JOURNAL OF UROLOGY (2003)
Comorbidity and karnofksy performance score are independent prognostic factors in Stage III non-small-cell lung cancer: An institutional analysis of patients treated on four RTOG studies
S Firat et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Perspectives on comorbidity and cancer in older patients: Approaches to expand the knowledge base
R Yancik et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
